CAMP and neoplasm: The results of immunophenotyping analyses in the GL261 orthotopic model indicated that the NE/CAMP+aPD‐1 combination treatment activated T cell‐ and NK cell‐mediated systemic immune responses, and decreased Treg activation in both spleen and CLNs as well as reduced the Treg population in the tumor tissue (Figure 5 and S8).